Nabriva Therapeutics AG (NBRV) Major Shareholder Hbm Healthcare Investments (Ca Sells 2,695 Shares of Stock

Nabriva Therapeutics AG (NASDAQ:NBRV) major shareholder Hbm Healthcare Investments (Ca sold 2,695 shares of the company’s stock in a transaction on Friday, July 7th. The stock was sold at an average price of $10.52, for a total transaction of $28,351.40. Following the completion of the transaction, the insider now owns 2,569,315 shares of the company’s stock, valued at $27,029,193.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Large shareholders that own more than 10% of a company’s shares are required to disclose their sales and purchases with the SEC.

Hbm Healthcare Investments (Ca also recently made the following trade(s):

  • On Friday, June 30th, Hbm Healthcare Investments (Ca sold 1,775 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $19,418.50.
  • On Monday, July 3rd, Hbm Healthcare Investments (Ca sold 13,127 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.94, for a total transaction of $143,609.38.
  • On Thursday, June 29th, Hbm Healthcare Investments (Ca sold 8,558 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total transaction of $93,795.68.
  • On Friday, April 28th, Hbm Healthcare Investments (Ca sold 15,939 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.02, for a total transaction of $175,647.78.
  • On Friday, April 21st, Hbm Healthcare Investments (Ca sold 2,622 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.04, for a total transaction of $28,946.88.
  • On Thursday, April 20th, Hbm Healthcare Investments (Ca sold 23,932 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.11, for a total transaction of $265,884.52.
  • On Thursday, April 13th, Hbm Healthcare Investments (Ca sold 32,831 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $11.24, for a total transaction of $369,020.44.
  • On Monday, April 10th, Hbm Healthcare Investments (Ca sold 90,594 shares of Nabriva Therapeutics AG stock. The stock was sold at an average price of $10.96, for a total transaction of $992,910.24.

Nabriva Therapeutics AG (NASDAQ:NBRV) remained flat at $10.50 during mid-day trading on Monday. 6,743 shares of the stock were exchanged. The company’s market cap is $28.57 million. Nabriva Therapeutics AG has a one year low of $3.52 and a one year high of $12.75. The firm has a 50 day moving average price of $9.87 and a 200-day moving average price of $9.52.

COPYRIGHT VIOLATION WARNING: This piece was reported by WKRB News and is owned by of WKRB News. If you are viewing this piece on another publication, it was illegally stolen and republished in violation of U.S. and international copyright & trademark laws. The legal version of this piece can be read at https://www.wkrb13.com/markets/2286389/nabriva-therapeutics-ag-nbrv-major-shareholder-hbm-healthcare-investments-ca-sells-2695-shares-of-stock.html.

Several institutional investors have recently modified their holdings of NBRV. Wellington Management Group LLP boosted its position in shares of Nabriva Therapeutics AG by 9.9% in the first quarter. Wellington Management Group LLP now owns 2,154,261 shares of the biotechnology company’s stock worth $25,830,000 after buying an additional 193,951 shares during the last quarter. Nationwide Fund Advisors acquired a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $2,074,000. Almanack Investment Partners LLC. acquired a new position in shares of Nabriva Therapeutics AG during the first quarter worth approximately $1,870,000. Finally, Renaissance Technologies LLC acquired a new position in shares of Nabriva Therapeutics AG during the fourth quarter worth approximately $103,000. 55.90% of the stock is owned by institutional investors and hedge funds.

NBRV has been the subject of several research reports. HC Wainwright reiterated a “buy” rating on shares of Nabriva Therapeutics AG in a research report on Friday, May 12th. Cantor Fitzgerald set a $16.00 target price on shares of Nabriva Therapeutics AG and gave the stock a “buy” rating in a research report on Thursday, May 11th. Needham & Company LLC reiterated a “buy” rating and issued a $15.00 target price on shares of Nabriva Therapeutics AG in a research report on Monday, March 27th. Zacks Investment Research upgraded shares of Nabriva Therapeutics AG from a “hold” rating to a “buy” rating and set a $11.00 price target for the company in a research report on Saturday, May 27th. Finally, ValuEngine upgraded shares of Nabriva Therapeutics AG from a “sell” rating to a “hold” rating in a research report on Saturday, June 24th. One analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Nabriva Therapeutics AG presently has a consensus rating of “Buy” and a consensus target price of $15.29.

About Nabriva Therapeutics AG

Nabriva Therapeutics AG is an Austria-based clinical-stage biopharmaceutical company engaged in the research and development of antibiotics to treat infections. Its lead product candidate, lefamulin, is a pleuromutilin antibiotic for systemic administration in humans. The Company develops both intravenous (IV) and oral formulations of lefamulin for the treatment of community-acquired bacterial pneumonia (CABP).

Insider Buying and Selling by Quarter for Nabriva Therapeutics AG (NASDAQ:NBRV)

This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2286389/nabriva-therapeutics-ag-nbrv-major-shareholder-hbm-healthcare-investments-ca-sells-2695-shares-of-stock.html

Receive News & Ratings for Nabriva Therapeutics AG Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics AG and related companies with MarketBeat.com's FREE daily email newsletter.

 


Leave a Reply

 
© 2006-2017 WKRB News.